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Background: The incidence of cardiovascular disease (CVD) in rheumatoid arthritis (RA) is increased compared to
the general population. Immune dysregulation and systemic inflammation are thought to be associated with this
increased risk. Early diagnosis with immediate treatment and tight control of RA forms a central treatment
paradigm. It remains unclear, however, whether using tumor necrosis factor inhibitors (TNFi) to achieve remission
confer additional beneficial effects over standard therapy, especially on the development of CVD.
Methods/Design: Coronary Artery Disease Evaluation in Rheumatoid Arthritis (CADERA) is a prospective cardiovascular
imaging study that bolts onto an existing single-centre, randomized controlled trial, VEDERA (Very Early versus Delayed
Etanercept in Rheumatoid Arthritis). VEDERA will recruit 120 patients with early, treatment-naïve RA, randomized to TNFi
therapy etanercept (ETN) combined with methotrexate (MTX), or therapy with MTX with or without additional synthetic
disease modifying anti-rheumatic drugs with escalation to ETN following a ‘treat-to-target’ regimen. VEDERA patients
will be recruited into CADERA and undergo cardiac magnetic resonance (CMR) assessment with; cine imaging, rest/
stress adenosine perfusion, tissue-tagging, aortic distensibility, T1 mapping and late gadolinium imaging. Primary
objectives are to detect the prevalence and change of cardiovascular abnormalities by CMR between TNFi and standard
therapy over a 12-month period. All patients will enter an inflammatory arthritis registry for long-term follow-up.
Discussion: CADERA is a multi-parametric study describing cardiovascular abnormalities in early, treatment-naïve RA
patients, with assessment of changes at one year between early biological therapy and conventional therapy.
Trials registration: This trial was registered with Current Controlled Trials (registration number: ISRCTN50167738) on 8
November 2013.
Keywords: Cardiovascular magnetic resonance, Rheumatoid arthritis, Biological therapy, Etanercept, Methotrexate,
Coronary artery disease, Aortic distensibility, MOLLI, Perfusion CMR, Late gadolinium enhancementBackground
Rheumatoid arthritis (RA) is one of the most common
autoimmune diseases affecting approximately 1% of the
population in the United Kingdom [1]. RA is a chronic,
systemic inflammatory arthritis and, if not adequately
controlled, can lead to significant joint damage and sub-
sequent functional impairment. Mortality is increased up* Correspondence: s.plein@leeds.ac.uk
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unless otherwise stated.to three-fold compared to the general population, largely
due to increased frequency of premature cardiovascular
disease (CVD), which causes up to 40% of mortality cases
in RA patients [2], and is as high as that of patients with
other major CVD risk factors such as type 2 diabetes melli-
tus [3]. It is accepted that CVD risk in RA is independent
of, and incremental to, traditional CVD risk factors [4],
with the likely predominant pathological process being im-
mune dysregulation leading to systemic inflammation [5],
however the exact mechanisms remain unclear. The in-
flammatory process, mediated through pro-inflammatory
cytokines such as tumor necrosis factor (TNF), is linked toal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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effects on lipid and glucose metabolism, blood pressure
and hemostatic factors [6]. Markers of RA severity are
strongly associated with adverse cardiovascular (CV) out-
comes in RA [7], with atherosclerosis itself being increas-
ingly viewed as an inflammatory-mediated process [8].
Arterial stiffness is associated with an increased risk of
CV events with a range of co-morbidities [9]. In patients
with RA without traditional CV risk factors, aortic pulse
wave velocity is higher than in controls [10] and correlates
with age, mean arterial pressure and C-reactive protein
(CRP). Echocardiography studies have shown that patients
with RA have high rates of diastolic dysfunction [11],
heart failure [12,13] and heart failure with preserved ejec-
tion fraction (EF) [14]. Positron emission tomography
(PET) in patients with rheumatic diseases without coron-
ary artery disease (CAD) shows lower myocardial blood
flow (MBF) reserve compared to controls, with an inverse
correlation to disease duration [15]. In a meta-analysis
of 22 studies, RA patients had a greater carotid intimal-
media thickness ((CIMT) a direct measure of the status
of the vascular wall and measure of atherosclerotic and
arteriosclerotic processes [16]) than controls [17], with
emerging evidence that CIMT is abnormal even in early
disease [18]. These findings are consistent with the con-
cept of microvascular pathology and accelerated athero-
sclerosis due to systemic inflammation in RA, which may
precede and contribute to the effects of CAD.
Early diagnosis of RA and immediate intervention with
conventional disease modifying anti-rheumatic drugs
(DMARDs) in a treat-to-target approach, with remission
the goal of treatment, is an internationally recommended,
established practice [19]. Biological DMARD (bDMARD)
treatments, first introduced at the turn of the century, are
highly effective tools to achieve this and have revolution-
ized outcomes in RA. The TNF-inhibitors (TNFi) were
the first bDMARD agents to be introduced, applied in the
methotrexate (MTX) failure population, with remarkable
structural benefits also observed. More recently however,
first-line TNFi studies in early RA have demonstrated
particularly high rates of remission induction, similar
or slightly greater than conventional DMARD, but with
superior structural benefits and the ability to achieve
drug-free remission [20-26]. In addition, reports have sug-
gested wider benefits of bDMARD therapy including
reduction in biomarkers associated with CVD [27,28].
Recent pilot data has shown that tocilizumab treatment
for over one year significantly increased left ventricular
ejection fraction and decreased left ventricular mass index
associated with disease activity [29].
CV clinical trials of TNFi treatments in RA are challen-
ging because of the small number of hard clinical CV mor-
tality endpoints in study populations [30], and being unable
to adjust for important confounders that differentiatebetween CV events that follow other pathophysiological
pathways [31]. As TNFi treatment is reserved for patients
with established, MTX-resistant diseases, observational
studies are inherently limited by a selection bias. Although
aggressive treat-to-target approaches with conventional
DMARDs are associated with impressive remission rates,
the use of bDMARD may offer a ‘window of opportunity’
in early RA by interrupting progression along the disease
continuum, and consequently may have the additional po-
tential to impact CVD.
Detection of cardiovascular disease in rheumatoid
arthritis
The imaging modalities currently used for the assess-
ment of CVD in RA are transthoracic echocardiography
(TTE), single-photon emission computed tomography
(SPECT) and cardiovascular magnetic resonance (CMR)
[32]. PET is recognized as the gold standard for MBF
quantification but is hindered by high cost and low avail-
ability and offers little functional information. SPECT is
commonly used for ischemia testing but, as with PET, it
cannot assess cardiac structure and exposes patients to a
significant dose of ionizing radiation [33]. TTE is a safe,
low-cost examination that can assess cardiac structure
and function and provides information on ischemia and
viability when combined with exercise and/or pharmaco-
logical stress. Poor acoustic windows can be a common
problem due to obesity or acoustic shadowing from the
lungs and reporting variability limits its reproducibility.
Cardiovascular magnetic resonance
CMR is widely recognized as a safe, sensitive, reprodu-
cible and comprehensive non-invasive imaging test to
detect CVD. Both anatomical and functional assessment
can be made with CMR. Left ventricular (LV) mass and
function can be measured more accurately than with
any other imaging method [34]. Aortic distensibility can
be reliably measured from the ascending or descending
aorta [35]. Tissue tagging provides measurements of re-
gional and global myocardial strain as an early marker of
contractile dysfunction [36]. We have shown in a large
study of patients with suspected angina that CMR can
detect myocardial ischemia with greater sensitivity than
nuclear perfusion imaging [37]. Dynamic contrast en-
hanced CMR methods combined with quantitative ana-
lysis can be used to estimate MBF at rest and during
hyperemic stress [38]. Perfusion CMR has demonstrated
reduced MBF reserve in asymptomatic adults with CVD
risk factors, suggesting it can detect preclinical path-
ology [39]. T1 mapping methods are used to measure
the extent of the extracellular matrix in the heart, which
expands in response to inflammation and fibrosis [40].
CMR has no harmful effects and multiple measurements
can be combined in a single imaging protocol [35].
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previous TTE studies, CMR shows that patients with RA
have reduced LV mass and EF [41]. No previous studies
have combined macrovascular, microvascular and detailed
myocardial assessment by CMR in RA, such that the full
potential of CMR for a comprehensive multi-parametric
and quantitative evaluation of CVD in RA has not yet
been realized.Hypotheses
We hypothesize that the CADERA study will determine,
using multi-parametric CMR, that i) subclinical CV path-
ology exists in patients with early, treatment-naïve RA,
ii) early aggressive control of RA can reduce this subclin-
ical CV pathology at one year from treatment initiation and
iii) TNFi offer additional benefit over and above conven-
tional DMARD in the burden of subclinical CV pathology.Methods/Design
Study design
CADERA bolts on to the VEDERA (Very Early versus
Delayed Etanercept in Rheumatoid Arthritis) trial, a pro-
spective longitudinal intervention study of patients with
early RA, randomized to either first-line TNFi therapy (eta-
nercept, ETN) and MTX or optimal synthetic DMARD
therapy. VEDERA is an investigator-initiated research
(IIR) study based at the Leeds Institute of Rheumatic and
Musculoskeletal Medicine, and is funded by an unre-
stricted educational grant that is part of an IIR agreement
with Pfizer. VEDERA is a phase IV, single-centre study of
120 patients with new-onset, treatment-naïve RA, ran-
domized to either immediate ETN and MTX combination
or initial MTX and a treat-to-target regimen (optimal,
standard conventional therapy approach); with step-up in
the latter group to ETN and MTX combination therapy in
patients failing to achieve a pre-defined target of remission
after 24 weeks. The aim of VEDERA is to assess for the
depth of remission (clinical and imaging) and immuno-
logical normalization induced by the treatment arms, as
well as to identify predictors of remission.
VEDERA patients will be recruited to CADERA and
undergo CMR at baseline (prior to treatment) as well as
after one and two years of treatment (see Figure 1). The
change in CVD status as defined by CMR between base-
line and follow-up in patients treated with early bio-
logical or optimal DMARD therapy will be determined.
The study flow chart is presented in Figure 1. At the
end of the study all patients will enter an inflamma-
tory arthritis registry based at the National Institute for
Health Research (NIHR) Leeds Musculoskeletal Biomedical
Research Unit (LMBRU).
The National Research Ethics Service Committee
Yorkshire and The Humber - Leeds West has approvedthe study protocol and other relevant documentation
(Research Ethics Committee reference: 10/H1307/138).
Enrolment criteria
Patients eligible for VEDERA will be recruited from the
Leeds Teaching Hospitals NHS Trust Rheumatology ser-
vice. The recruitment period is expected to last up to
36 months. All patients recruited to VEDERA will be of-
fered inclusion to the CADERA study. CADERA CMR
scans will be performed and analyzed at Leeds General
Infirmary. The study will be performed in accordance
with the Declaration of Helsinki (October 2000), with all
patients providing informed written consent.
Inclusion criteria for VEDERA, and therefore CADERA,
are patients diagnosed with RA according to the 2010
American College of Rheumatology/The European League
Against Rheumatism (ACR/EULAR) criteria (Table 1),
who have not yet received therapy with DMARDs, have
early (symptoms for less than one year) active disease
(clinical or imaging evidence of synovitis and Disease
Activity Score in 28 joints with Erythrocyte Sedimentation
Rate (DAS28-ESR) ≥3.2) and at least one poor prognostic
factor (anti-citrullinated peptide antibody (ACPA) +/−
abnormal power doppler in at least one joint).
Exclusion criteria are previous treatment with DMARDs,
known CVD, contraindications to TNFi therapy (or severe
co-morbidity that would in the clinician’s opinion be asso-
ciated with unacceptable risk of receiving TNFi therapy)
and contraindications to CMR, (which include renal failure
(estimated Glomerular Filtration Rate (eGFR) <30 ml/
min/1.73 m2), known allergy to gadolinium-based contrast
agents and contraindications to adenosine (asthma or
high-grade heart block)).
Primary outcome measure
The primary outcome measure is aortic distensibility. It
will be measured and quantified at baseline and at one
year in each arm of the study. Increased arterial stiffness
is associated with an increased risk of CV events [9]. It
can be measured by pulse wave velocity or as distensibil-
ity of the aorta, but requires careful correction for age
and blood pressure. It has previously been shown that
aortic distensibility relates to clinical outcome and that
TNFi improve aortic distensibility [27]. We performed a
pilot study in 10 patients with RA (disease duration 20 ±
9.6 years) and matched by age and gender to 10 asymp-
tomatic subjects without RA. Aortic distensibility was
significantly different in RA patients, with a mean
and standard deviation of 1.83 ± 0.4 cm2 versus 2.6 ±
0.6 cm2 in controls. LV volumes and mass were simi-
lar between groups and LV strain and twist showed
trends towards a reduction in RA patients, but without
reaching statistical significance. Our pilot data therefore
suggested CV abnormalities in patients with RA in several
Figure 1 Coronary Artery Disease Evaluation in Rheumatoid Arthritis (CADERA) study flow diagram. *Etanercept non-responders or intolerance
managed at physician’s discretion. #Methotrexate for duration of study, addition of other DMARDs at week eight if not in remission and escalated to
etanercept at week 24 if not in remission. ~Etanercept discontinued at the primary endpoint unless clinically indicated and at physician’s
discretion. DAS, disease activity score; DMARD, disease modifying anti-rheumatic drug; HRUS, high-resolution ultrasound; LTHT, Leeds
Teaching Hospitals NHS Trust; MCP, metacarpophalangeal; RA, rheumatoid arthritis; TT, treat-to-target; VEDERA, Very Early versus Delayed
Etanercept in Rheumatoid Arthritis.
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reaching statistically significant difference even in the
small sample size.
Longitudinal changes of outcome measures in response
to therapy will be measured and compared between the
two treatment arms at baseline, one and two year time
points. Secondary outcome measures are i) myocardial per-
fusion reserve, ii) LV strain and twist, iii) LVEF and iv) LVmass. Exploratory outcome measures are pre- and post-
contrast T1 mapping, extra-cellular volume (ECV) and bio-
marker measurements.
Significant differences (expressed as P <0.05) of CV
abnormalities detected by CMR between the two treat-
ment arms will be presented, and the magnitude of
this difference will be expressed as a 95% confidence
interval.




1 large joint 0
2-10 large joints 1
1-3 small joints (large joints not counted) 2
4-10 small joints (large joints not counted) 3
>10 joints (at least one small joint) 5
Serology
Negative RF AND negative ACPA 0
Low positive RF OR low positive ACPA 2





Normal CRP AND normal ESR 0
Abnormal CRP OR abnormal ESR 1
A score of six or more equates to definite RA. This requires that the patient
has at least one joint with definite synovitis and that the synovitis is not better
explained by another disease. The score may be retrospective or prospective.
ACPA, anti-citrullinated peptide antibody; CRP, C-reactive protein; ESR, erythrocyte
sedimentation rate; RF, rheumatoid factor.
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Power calculations are based on a previous study by
Ikonomidis et al. [28]. We assumed an effect size of 2.46
cm2dyne−110−6, representing 75% of the difference be-
tween treated (Anakinra) and non-treated RA patients re-
ported by Ikonomidis et al. [28]. Mean aortic distensibility
at baseline to post-treatment for treated and non-treated
patients was 1.56 cm2dyne−110−6 and 4.6 cm2dyne−110−6,
respectively. The standard deviation (SD) of the post-
treatment measurements in the Anakinra group was 3.2
cm2dyne−110−6 and a more conservative estimate of 3.5
cm2dyne−110−6 has been used in the CADERA power cal-
culation. Assuming an SD of 3.5 cm2dyne−110−6, a power
of 70%, 80% and 90% would be achieved at 5% significance
level in a two-tailed independent samples Student’s t-test
with 26, 33 and 44 patients respectively in the primary
outcome measure of aortic distensibility in each treatment
group (30, 38 and 50 when adjusted for 10% dropout).
Both treatment arms will be compared with primary
outcome aortic distensibility from baseline to one-year
follow-up, as well as other outcome measures. Analysis
will be conducted in the R environment for statistical
computing (R Core Team, 2012. R: A language and en-
vironment for statistical computing. R Foundation for
Statistical Computing, Vienna, Austria). Exploratory data
analysis will be used to determine if parametric (independ-
ent samples Student’s t-test) or non-parametric (Wilcoxonrank sum test) analyses are appropriate, and to summarize
the distribution of aortic distensibility and change in other
outcome measures across the two treatment arms. These
analyses will also allow the credibility of an equal variance
assumption to be assessed in parametric modeling and to
be appropriately modeled [42]. All patients meeting eligi-
bility criteria will be included in the analyses and these will
be conducted at the end of the recruitment period. Ex-
ploratory subgroup analyses will be conducted separately
by other comorbidities, a maximum of two to three that
are clinically plausible, with appropriate correction for
multiple testing [43]. Interactions between subgroups and
interactions between CMR findings and biomarkers will
be explored through building a linear model with inter-
action terms [44]. Patterns of CVD pathology in RA pa-
tients will be described. Treatment effects on secondary
outcome measures and effects at the two-year follow-up
point will be analyzed in an equivalent manner.
Missing data
The numbers of patients with missing data for one or
more CMR measurements, and the number of uninter-
pretable images will be reported. Patients with missing
data for any CMR measurement will be excluded from
any comparison involving that measurement.
Test conduct
The number of patients referred from VEDERA and fail-
ing to complete the CMR protocol will be reported,
along with the reason why the test failed. The duration
of the CMR scan will also be summarized.
Cardiac magnetic resonance investigation details
Our group has well-established multi-parametric protocols
that have been validated in other populations [45]. CMR
will be performed on a dedicated 3 T Philips Achieva TX
system equipped with a 32-channel coil, vectorcardio-
graphic triggering and multi-transmit technology (Philips
Healthcare, Best, The Netherlands). Patients will be asked
to avoid caffeine for 24 hours prior to the scan. The CMR
protocol (Figure 2) lasts approximately 60 minutes and
will comprise of:
1. Low-resolution survey, reference scans and
localizers. Following survey and reference scans, the
heart’s short axis, vertical long axis and horizontal
long axis will be defined with a series of cine images
(balanced steady-state free precession acquisition
(bSSFP), echo time (TE) 1.48 ms, repetition time
(TR) 3.0 ms, flip angle 45°, field of view 320 to
420 mm according to patient size, slice thickness
10 mm and 30 phases per cardiac cycle).
2. Baseline T1 mapping. One slice will be acquired
at the LV short axis using an electrocardiogram
Figure 2 Coronary Artery Disease Evaluation in Rheumatoid Arthritis (CADERA) cardiac magnetic resonance protocol. LGE, late
gadolinium enhancement; LV, left ventricular; MOLLI, modified Look-Locker inversion method; SPAMM, spatial modulation of magnetization.
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(MOLLI) method to acquire 11 images (3-3-5
acquisition with 3 × R-R interval recovery epochs)
in a single end-expiratory breath hold (voxel
size 1.7 × 2.14 × 10 mm3 trigger delay at
end-diastole, flip angle 35° and field of view 320
to 420 mm) [46,47].
3. Adenosine stress first-pass myocardial perfusion
imaging (spoiled Turbo Gradient Echo, 5 × k-t
Broad-use Linear Acquisition Speed-up Technique,
11 training profiles, 1.31 × 1.32 × 10 mm3 acquired
resolution, pre-pulse delay 100 ms, acquisition shot
123 ms/slice, three short axis slices) [48]. Intravenous
adenosine will be administered at 140 mcg/kg/min for
three minutes under continuous ECG monitoring.
Adequate hemodynamic response is assessed by
either i) heart rate increase by ≥10%, ii) systolic blood
pressure decrease of ≥10 mmHg or iii) symptoms
attributed to adenosine administration. If there is
inadequate hemodynamic response then the dose
will be increased to 170 and then to 210 μg/kg/min for
a further two minutes until hemodynamic response is
achieved. The contrast injection will be performed
using a dual-bolus technique, by intravenous route
in the ante-cubital fossa, of 0.1 mmol/kg of
gadolinium-DTPA (diethylene triamine pentaacetic
acid) (gadopentetate dimeglumine; Magnevist, Bayer,
Berlin, Germany) for the main bolus, preceded by the
same volume of a 10% dilute contrast agent dose for
the pre-bolus, both administered at a rate of 4.0 ml/s,
followed by a saline flush using a using a power
injector (Spectris, Solaris, Pennsylvania, United
States) [49].
4. Resting wall motion and LV function. Cine image
stack covering the entire heart in the LV short axis
plane at one slice per breath-hold in end-expiration
and parallel to the mitral valve annulus (bSSFP,
multiphase, 10 to 12 contiguous slices, spatial
resolution 2.0 × 1.63 × 8 mm3 and 30 cardiac
phases) [50,51].5. Tissue tagging for strain analysis and diastology.
Spatial modulation of magnetization pulse sequence
(spatial resolution 1.51 × 1.57 × 10 mm3, tag separation
7 mm, ≥18 phases, typical TR/TE 5.8/3.5 ms and flip
angle 10°).
6. Aortic distensibility. Cine images of the ascending
aorta (50 phases) at the level of the PA bifurcation
and the descending aorta, transverse to the vessel
according to Lee et al. [35]. For aortic stiffness, blood
pressure and heart rate are recorded immediately
prior to the multi-phase SSFP cine image (24 phases).
7. Resting first-pass myocardial perfusion study.
Pulse sequence, slice positioning and injection
characteristics identical to the stress perfusion
scan as above in step 3.
8. Late gadolinium enhancement (LGE). Performed
between 10 and 15 minutes after step 7. Inversion
recovery-prepared T1-weighted gradient echo. The
optimal inversion time to null signal from normal
myocardium will be determined using a modified
Look-Locker approach [52]. Typical parameters: TE
2.0 ms, TR 3.5 ms, flip angle 25°, acquired spatial
resolution 1.54 × 1.76 × 10 mm3. Inversion time
adjusted according to variable TI scout. Alternate
heart beat acquisitions by navigator is an option
for poor breath holders. Performed in 10 to 12
short axis slices with further slices acquired in the
vertical and horizontal long axis orientations, or
phase-swapped, if indicate based on LGE imaging
obtained, wall-motion or perfusion defects.
9. Post-contrast T1 mapping 15 minutes following last
contrast injection at step 7. Acquisition and slice
positioning as above in step 2.
T1 mapping, tissue tagging and perfusion imaging are
performed in three identical short-axis positions. These
will be determined using the ‘three-of-five’ approach by
acquiring the central three slices of five parallel short-
axis slices spaced equally from mitral valve annulus to
LV apical cap [53].
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Image analysis will be performed offline, blinded to patient
characteristics and treatment arm, using commercially
available software (cvi42 version 4.1.3, Circle Cardiovascular
Imaging Inc., Calgary, Canada and inTag version 1.0,
CREATIS lab, Lyon, France) according to international
standards for reporting of CMR studies [54].
LV volume and EF will be calculated from the short
axis cine-stack using standard criteria to delineate car-
diac borders [54]. Regional wall motion in 17 cardiac
segments will be graded visually. Aortic cross sectional
measurements will be made by manual planimetry of the
endovascular-blood pool interface, at the times of max-
imal and minimal distension of the aorta. Aortic disten-
sibility, compliance and stiffness index are calculated by
standard methods using blood pressure measurements
taken at the time of image acquisition with formulas and
definitions listed in Table 2 [55].
Native and post-contrast myocardial T1 will be mea-
sured [56]. Care will be taken to ensure a conservative
region of interest and to avoid partial-volume effects from
neighboring tissue or blood pool. Regions of interest are
manually motion-corrected as required. The reciprocal of
T1 is calculated as R1. ECV is calculated using the follow-
ing equation [57]:
ECV ¼ 1‐hctð Þ  R1myo post‐R1myo pre
R1blood post‐R1blood pre
ð1Þ
Where hct is the hematocrit. Myo pre and myo post are
the pre-contrast and post-contrast myocardial T1 values.
Blood pre and blood post are the pre-contrast and post-
contrast blood pool T1 values. Strain analysis will use data
from the tagged cine series. Endocardial and epicardial
contours are drawn by a semi-automated process for each
slice. Peak circumferential systolic strain and rotation will
be calculated for the three short axis slices at the level of
apex, mid-ventricle and base. LV twist is calculated by
subtracting the basal rotation from the apical rotation.
The method of determining torsion takes the radius and
length of the heart into account, describing the torsion as
the circumferential-longitudinal shear angle. This makes
the measurement comparable between hearts of different
sizes and is related to fiber orientation and processes in
the myocardium [58,59]. Basal and apical radius is calcu-
lated from measuring area by epicardial contours on cineTable 2 Definitions and formulas of parameters used in the a
Parameter Definition
Aortic Compliance The absolute change in vessel diameter (or
Aortic Distensibility The absolute change in vessel diameter (or
Stiffness Index The ratio of the natural logarithm of SBP/DB
Δ; change in; D, diameter; d, diastole; ln, natural logarithm; P, pressure; s, systole. Aimaging in diastole at the same slice location as the tagged
images. Base-to-apex length is determined by subtracting
the slice locations. The equation used to determine tor-
sion is:
Torsion¼ Peak Twist Apical RaduisþBasal radiusð Þ
2Apex to Base length
ð2Þ
Myocardial perfusion will be assessed by visual compari-
son of stress and rest CMR perfusion scans (16 segments
of the modified 16 segment American Heart Association/
American College of Cardiology model) [60] with scores
of 0 (normal), 1 (equivocal), 2 (non-transmural ische-
mia <50%), 3 (non-transmural ischemia ≥50%) or 4
(transmural ischemia). In addition, quantitative MBF
estimates will be obtained using Fermi-constrained decon-
volution, or other methods and myocardial perfusion
reserve (MPR) calculated by dividing stress by rest MBF
values [38].
LGE images will be analyzed visually by two experi-
enced observers and any relevant patterns of enhance-
ment are described based on a 17-segment model with
scores of 0 (no hyperenhancement), 1 (1 to 25% mural
thickness), 2 (26 to 50% mural thickness), 3 (51 to 75%
mural thickness) or 4 (>75% mural thickness) allocated
to each segment. Quantitative analysis of LGE will also
be performed. LGE volume will be calculated across the
whole LV stack by the modified Simpson’s method. To
avoid confounding for artifacts, a conservative threshold
for LGE is employed at five SDs from remote, normal
myocardium. The amount of LGE will be presented as a
percentage against normal myocardium.
Reproducibility
CMR measurements have been validated in previous
reproducibility studies. In our hands, the inter- and
intra-observer reproducibility for measurement of aortic
distensibility by CMR is excellent. In a clinical study of
49 volunteers, the intra-observer mean difference for
diastolic (minimum) aortic volume was 0.009 ± 0.039 ml
and the mean difference for systolic (maximum) aortic
volume was 0.0075 ± 0.039 ml (P = not significant). The
coefficient of variation (CoV) in the diastolic and systolic
measurements were 1.4% and 1.1%, with an intra-class
correlation coefficient (ICC) of r = 0.998 and r = 0.998,ssessment of arterial stiffness
Formula
area) for a given change in pressure ΔD/ΔP
area) for a given change in pressure ΔD/(ΔP × D)
P to the relative change in diameter ln(Ps/Pd)/((Ds-Dd)/Dd)
dapted from Oliver and Webb [55].
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shows an intra-observer CoV for circumferential strain
of 4.3%, and 1.2% for LV twist (n = 12). The inter-study
CoV of circumferential strain is 3.7% and 9.6% for LV
twist. The ICC shows excellent intra-observer, inter-
observer and inter-study reproducibility of circumferen-
tial strain, ranging from 0.95 to 0.98. The ICC suggested
excellent intra-observer and inter-observer reproducibil-
ity (0.97 and 0.95, respectively) of LV twist and good
inter-study reproducibility of LV twist (0.67) [62]. Quan-
titative perfusion analysis has an intra-observer CoV of
13 to 18% and an inter-observer CoV of 8 to 15%. In a
pilot study of 11 volunteers, the inter-observer mean dif-
ference was 0.22 ± 14.82% to 4.53 ± 12.83%, and the intra-
observer mean difference was 4.51 ± 13.22% to 7.78 ±
20.19% [63]. The inter- and intra-observer ICC of quanti-
tative perfusion by CMR has been previously shown to be
0.83 and 0.80, respectively [64]. In this study, repeated
measurements of 12 randomly selected scans, with blind-
ing to the original measurements, will be performed for
reproducibility analysis.
Biomarkers
As part of the exploratory objectives, CADERA will en-
able linkage of biomarkers to CMR measurements of
CVD. Specifically, the following will be clinically evalu-
ated: rheumatoid factor (RF), ACPA, CRP, ESR, lipid
profile, high-sensitivity CRP, serum amyloid A, fibrino-
gen, adiponectin, interleukin-6, TNF, intercellular adhe-
sion molecule-1, vascular cellular adhesion molecule 1,
CD40 ligand and N-terminal prohormone of B-type
natriuretic peptide.
Annual follow-up and the Inflammatory Arthritis disease
CONtinuum (IACON) study
Created in 2010 at the NIHR LMBRU, the IACON
(Inflammatory Arthritis disease CONtinuum) study is
a major longitudinal cohort study in inflammatory arth-
ritis. This facilitates collection of CVD outcome measure-
ments in patients with inflammatory arthritis at Leeds
from disease inception onwards. On completion of the
study, all CADERA study patients will enter IACON, per-
mitting continued follow-up annually or as clinically indi-
cated. There is no fixed endpoint for data collection and
study duration of IACON. CMR findings will be linked
to clinical outcome through long-term follow-up in this
registry.
Safety and adverse events
CMR is a standard clinical imaging modality in everyday
clinical use and risks to the study participants are small.
Adenosine stress agents carry a small risk of adverse
effects including transient atrio-ventricular block and
bronchospasm. CMR contrast agents carry a low riskof allergic reactions (approximately 1:10,000). To avoid
the development of nephrogenic systemic fibrosis relating
to some CMR contrast agents, patients with renal failure
and an eGFR of less than 30 ml/min/1.73 m2 will not be
recruited. All serious adverse events that occur as a result
of the CMR will be reported without formal statistical
testing being undertaken.
Discussion
Early diagnosis and immediate treatment of new, onset,
treatment-naïve RA is crucial to ensure the best possible
treatment outcomes. Studies demonstrate TNFi agents
confer additional structural benefit but, in particular, may
be able to modulate disease progression in a proportion of
patients. It remains unclear whether use of non-bDMARD
(MTX) impedes this potential effect. We postulate with
the VEDERA study that first-line TNFi therapy is qualita-
tively and quantitatively superior, with better clinical,
structural and immunological outcomes when compared
with non-biological DMARDs. The bolt-on CADERA
study will provide a comprehensive CV evaluation of the
VEDERA population to assess the prevalence and severity
of CVD in a treatment-naïve patient population of new-
onset RA with comparison to clinical parameters, such as
RA disease severity. The study will also evaluate whether
effective RA disease control (remission) can improve CVD
as assessed by CMR and, importantly, whether achieving
remission through first-line TNFi offers any additional
benefit over initial synthetic DMARD-induced remission.
With linkage of CMR assessment, CVD biomarkers and
long-term outcomes with follow-up in the IACON regis-
try, we hope to improve our understanding of the patho-
physiology of CVD in the RA population. The knowledge
gained from these studies may contribute towards more
effective use of targeted therapies for patients with RA
and improve long-term health-economic benefits.
Trial status
This trial is ongoing. Patient recruitment and follow-up
is underway. Recruitment began in February 2012 and is
expected to end in June 2015.
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